540 / 1631
Eligible patients:
•
CD20+ FL, Waldenstrom's
macroglobulinemia (WM),
marginal-zone lymphoma
(MZL), small lymphocytic
lymphoma (SLL), mantle
cell lymphoma (MCL);
elderly
•
No previous treatment
•
Stage III or IV
R
A
N
D
O
M
I
Z
E
Bendamustine-Rituximab (BR)
Bendamustine 90 mg/m
2
Days 1-2
Rituximab 375 mg/m
2
Day 1
CHOP-Rituximab (R-CHOP)
Cyclophosphamide 750 mg/m
2
Day 1
Doxorubicin 50 mg/m
2
Day 1
Vincristine 1.4 mg/m
2
Day 1
Prednisone 100 mg/m
2
Days 1-5
Rituximab 375 mg/m
2
Day 1
•
Primary objective
‐
To prove the noninferiority of BR vs. R-CHOP defined as a decrease of <10% in PFS after 3 years
•
Secondary objectives
‐
Response rates, time to next treatment, event-free survival, OS
‐
Acute and late toxicities, infectious complications
‐
Stem cell mobilization capacity in younger patients
(N=549)
BR vs. R-CHOP The StiL Study
Rummel M et al. Lancet, 381.1203 - 1210